EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth ANN ARBOR, MI / ACCESSWIRE / May 15, 2025 / Zomedica Corp. (OTCQB: ZOMDF) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2025. “We are pleased with our performance in the first quarter as we posted record year over year revenue for the 17th straight quarter,” said Larry Heaton, President and Chief Executive Officer of Zomedica. “Bolstered by continued and robust usage of our consumable PulseVet® products, and the continued growth and adoption of our TRUFORMA® products, we were able to deliver the strongest first quarter in company history. “Through further expansion of our portfolio, highlighted by the introduction of our new VETIGEL® product line, and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable us…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
ZOMEDICA CORP
ZOMDFOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 15, 2025, Zomedica Corp. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.…
Company context
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUSTM Zero Touch® monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million and maintains a strong balance sheet with approximately $44 million in liquidity as of June 30, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.